Disease Info Card

Adenoid Cystic Carcinoma

Information about Adenoid Cystic Carcinoma: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Adenoid Cystic Carcinoma

Most recent studies have shown that Adenoid Cystic Carcinoma shares some biological mechanisms with adenocarcinoma, adenoma, bronchial-neoplasms, carcinoma, cell-invasion, eccrine-dermal-cylindroma, lung-neoplasms, malignant-neoplasms, malignant-paraganglionic-neoplasm, malignant-squamous-cell-neoplasm, mixed-salivary-gland-tumor, mucoepidermoid-carcinoma, neoplasm-metastasis, neoplasm-recurrence-local, neoplasms, parotid-neoplasms, salivary-gland-diseases, salivary-gland-neoplasms, skin-neoplasms, tracheal-neoplasms.

Among the many pathways, these few ones have gauged particular interests from scientists studying Adenoid Cystic Carcinoma, and have been seen in publications frequently: Angiogenesis, Cell Adhesion, Cell Cycle, Cell Death, Cell Differentiation, Cell Growth, Cell Proliferation, Dedifferentiation, Dehiscence, Enucleation, Induction Of Apoptosis, Invasive Growth, Localization, Methylation, Mitosis, Oncogenesis, Pathogenesis, Rna Interference, Secretion

Quite a number of genes have been found to play important roles in Adenoid Cystic Carcinoma, such as ACACA, ACAT1, BCL2A1, CYLD, EGFR, ERBB2, KIT, MUC1, PCNA, PGR, POMC, SLC25A5, TP53, TP63, VEGFA, VIM. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.

Adenoid Cystic Carcinoma Related Genes

click to see detail information for each gene

ACACA ACAT1 BCL2A1
CYLD EGFR ERBB2
KIT MUC1 PCNA
PGR POMC SLC25A5
TP53 TP63 VEGFA
VIM